Cancer Biomarker Market Research
Report: By Types (Protein Biomarker, Genetic Biomarker), By Applications
(Diagnostic, Prognostic, Therapeutic), By End Users (Pharmaceutical and
Biotechnology Companies, Diagnostic Companies) – Forecast till 2023
Market Research Future (MRFR) has
released a new market research report on the global cancer biomarker market.
The global cancer biomarker market is expected to grow at a CAGR of 15.8% over
the forecast period from 2017 to 2023, according to the report. The report
presents a detailed projection for the global cancer biomarker market’s growth
over the forecast period based on statistics revealing the market’s historical
trajectory and leading components. The leading segments and key market players
int the global cancer biomarker market, as well as the market’s key drivers and
restraints, are studied in the report. The global Cancer
Biomarker Market is expected to grow at a CAGR of 15.8% during the forecast
period, 2017-2023.
Cancer biomarkers are various
molecules released during the formation and growth of a cancerous tumor. These
molecules can be found in the actual site of the tumor as well as in connective
tissues and other tissues where the tumor may have metastasized. These
molecules can be detected through various diagnostic tests to detect and study
the tumor. Cancer biomarkers are a vital means to identifying and recognizing
the threat of cancerous tumors, as they provide a foolproof way of determining
the tumor’s progress. The demand to develop more accurate and faster methods to
detect and identify cancer biomarkers has grown rapidly over the last few years
as a result of the growing prevalence of cancer. This is likely to be the major
driver for the global cancer biomarker market over the forecast period.
Segmentation:
The global cancer biomarker
market is segmented on the basis of type, application, and end user.
On the basis of type, the global
cancer biomarker market is segmented into protein biomarkers, genetic biomarkers,
and others.
On the basis of application, the
cancer biomarker market is segmented into diagnostic, prognostic, and
therapeutic. The diagnostic sub-segment is further classified into imaging and
non-imaging.
On the basis of end use, the
market is segmented into pharmaceutical and biotechnology companies, diagnostic
tool companies, healthcare IT/big data companies, and clinical laboratories.
Browse Complete Report : https://www.marketresearchfuture.com/reports/cancer-biomarker-market-5378
Regional Analysis:
The global cancer biomarker
market is segmented by region into the Americas, Europe, Asia Pacific, and the
Middle East and Africa.
North America and Europe hold the
dominant shares in the global cancer biomarker market, with Europe holding the
larger share at present and North America expected to hold the largest market
share by the end of the forecast period. The healthy presence of a stable
cancer research environment, along with the steady government support for
cancer research and advanced cellular research, has been the vital market
driver for the cancer biomarker market in North America and Europe. The number
of clinical trials related to cancer research and other cellular research
applicable in cancer biomarker study is growing in these regions, which is
likely to remain a major driver for the cancer biomarker market in these
regions over the forecast period.
The increasing expenditure caused
by cancer is likely to be a major driver for the cancer biomarker market in
North America and Europe. Cancer causes about 14 million new cases each year
globally, according to the WHO, and the number is likely to grow further over
the forecast period, leading to growing efforts in the healthcare sector to
eradicate the problem. Cancer treatment is a major part of the overall
healthcare expenditure around the world and is likely to remain so over the
forecast period, driving the demand from the cancer biomarker market.
Asia Pacific is also likely to
exhibit rapid growth in the global cancer biomarker market over the forecast
period due to the growing prevalence of cancer in Southeast Asian countries and
the increasing efforts being taken by governments as well as private
corporations to find effective cures for cancer.
Competitive Analysis:
Leading players in the global
cancer biomarker market include F. Hoffman-La Roche AG, Abbott Laboratories,
Bristol-Myers Squibb, Eli Lilly and Company, Pfizer Inc., Qiagen NV, Thermo
Fisher Scientific Inc., Illumina Inc., Novartis AG, GSK, Merck & Co. Inc.,
Bio-Rad Laboratories, PerkinElmer Inc., and Becton, Dickinson and Company.
Industry Updates:
In February 2019, Corvus
Pharmaceuticals Inc. presented the biomarker and clinical results from its
leading oncology research programs.
In January 2019, researchers in
Kobe University’s Medical Device Fabrication Engineering Center developed a new
highly sensitive method to detect chemicals that carry out intercellular
communication in cancers, which could act as an effective biomarker for the
disease.
No comments:
Post a Comment